CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-09-02 | GADICKE ANSBERT Director | Sale | −2,178 | $29.46 | $64K | 256,792 |
| 2021-09-02 | GADICKE ANSBERT Director | Sale | −15,757 | $29.46 | $464K | 7,736,816 |
| 2021-09-01 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −5,714 | $29.47 | $168K | 7,752,573 |
| 2021-09-01 | GADICKE ANSBERT Director | Sale | −790 | $29.47 | $23K | 258,970 |
| 2021-09-01 | GADICKE ANSBERT Director | Sale | −5,714 | $29.47 | $168K | 7,752,573 |
| 2021-08-31 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −1,285 | $29.43 | $38K | 7,759,840 |
| 2021-08-31 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −1,553 | $30.14 | $47K | 7,758,287 |
| 2021-08-31 | GADICKE ANSBERT Director | Sale | −177 | $29.43 | $5K | 259,975 |
| 2021-08-31 | GADICKE ANSBERT Director | Sale | −1,285 | $29.43 | $38K | 7,759,840 |
| 2021-08-31 | GADICKE ANSBERT Director | Sale | −215 | $30.14 | $6K | 259,760 |
| 2021-08-31 | GADICKE ANSBERT Director | Sale | −1,553 | $30.14 | $47K | 7,758,287 |
| 2021-08-30 | GADICKE ANSBERT Director | Sale | −4,285 | $29.30 | $126K | 260,152 |
| 2021-08-30 | GADICKE ANSBERT Director | Sale | −31,001 | $29.30 | $908K | 7,761,125 |
| 2021-08-30 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −31,001 | $29.30 | $908K | 7,761,125 |
| 2021-08-27 | GADICKE ANSBERT Director | Sale | −1,846 | $29.09 | $54K | 264,437 |
| 2021-08-27 | GADICKE ANSBERT Director | Sale | −13,357 | $29.09 | $389K | 7,792,126 |
| 2021-08-27 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −13,357 | $29.09 | $389K | 7,792,126 |
| 2021-08-25 | UBS Oncology Impact Fund L.P. 10% owner | Sale | −1,713 | $29.09 | $50K | 7,805,483 |
| 2021-08-25 | GADICKE ANSBERT Director | Sale | −237 | $29.09 | $7K | 266,283 |
| 2021-08-25 | GADICKE ANSBERT Director | Sale | −1,713 | $29.09 | $50K | 7,805,483 |
Page 18 of 23 · 446 trades